Castle Biosciences (NASDAQ:CSTL) Stock Price Expected to Rise, KeyCorp Analyst Says

Castle Biosciences (NASDAQ:CSTL) had its target price increased by analysts at KeyCorp from $35.00 to $40.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp‘s price objective points to a potential upside of 16.96% from the company’s previous close.

Several other brokerages also recently commented on CSTL. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 29th. Mizuho initiated coverage on Castle Biosciences in a report on Thursday, October 29th. They set an “outperform” rating and a $60.00 price target on the stock. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research report on Friday, July 31st. Finally, BTIG Research increased their price objective on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $44.88.

Castle Biosciences Stock Down 4.3%

NASDAQ:CSTL opened at $34.20 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The firm has a market cap of $1.04 billion, a P/E ratio of -51.82 and a beta of 1.00. Castle Biosciences has a fifty-two week low of $17.72 and a fifty-two week high of $44.28. The firm has a 50-day simple moving average of $34.28 and a two-hundred day simple moving average of $28.57.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $101.95 million for the quarter, compared to the consensus estimate of $92.77 million. Analysts predict that Castle Biosciences will post -1.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tobin W. Juvenal sold 6,578 shares of the firm’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $36.42, for a total value of $239,570.76. Following the transaction, the insider directly owned 38,853 shares in the company, valued at $1,415,026.26. This trade represents a 14.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek Maetzold sold 8,580 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was sold at an average price of $31.91, for a total value of $273,787.80. Following the completion of the transaction, the insider owned 12,484 shares in the company, valued at approximately $398,364.44. This trade represents a 40.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 126,184 shares of company stock valued at $4,324,506. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CSTL. BlackRock Inc. purchased a new position in Castle Biosciences in the second quarter worth about $78,513,000. Jefferies Financial Group Inc. bought a new stake in shares of Castle Biosciences during the 2nd quarter valued at about $15,440,000. Renaissance Technologies LLC grew its stake in shares of Castle Biosciences by 8.1% during the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after purchasing an additional 39,700 shares during the period. AIGH Capital Management LLC bought a new stake in shares of Castle Biosciences during the 2nd quarter valued at about $13,001,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Castle Biosciences during the 2nd quarter valued at about $7,912,000. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q3 2026 revenue rose 24% year over year to $102.9 million, above analysts’ expectations. The company’s loss of $0.13 per share was also narrower than consensus estimates of roughly $0.35–$0.38 per share. Castle Biosciences Reports Third Quarter 2026 Results
• Positive Sentiment: Castle raised its 2026 revenue guidance to $385 million–$395 million, up from $365 million–$375 million. TissueCypher test report volume grew 47% year over year in Q3, and the company cited a target of 50%–52% volume growth, supporting the improved outlook. Castle Biosciences signals 2026 revenue outlook
• Negative Sentiment: The company still posted a quarterly loss, and its loss per share widened from $0.02 in the year-ago quarter to $0.13. Persistent unprofitability may temper the positive impact of revenue growth and improved guidance. Castle Biosciences reports Q3 loss, beats revenue estimates

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.